allogeneic Myeloma GM-CSF Vaccine
/ Sidney Kimmel Comprehensive Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 29, 2024
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
(clinicaltrials.gov)
- P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2024 ➔ Dec 2024
Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology
February 24, 2023
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
(clinicaltrials.gov)
- P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2023 ➔ Sep 2024 | Trial primary completion date: Jan 2023 ➔ Mar 2024
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
September 14, 2022
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
(clinicaltrials.gov)
- P2 | N=54 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting ➔ Active, not recruiting
Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 3
Of
3
Go to page
1